Open Source Securities released a research report on April 26 stating that it gave Ling Rui Pharmaceutical (600285.SH) a purchase rating. The main reasons for the rating include: 1) impressive revenue growth rate for patch, tablet and capsule products, and a further increase in gross margin; 2) strengthening brand building to create new potential, and channel innovation to improve marketing efficiency. (Mainichi Keizai Shimbun)
开源证券4月26日发布研报称，给予羚锐制药（600285.SH）买入评级。评级理由主要包括：1）贴剂、片剂及胶囊剂产品营收增速亮眼，毛利率进一步提升；2）加强品牌建设打造新势能，渠道创新提升营销效率。（每日经济新闻）
Open Source Securities released a research report on April 26 stating that it gave Ling Rui Pharmaceutical (600285.SH) a purchase rating. The main reasons for the rating include: 1) impressive revenue growth rate for patch, tablet and capsule products, an
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.